Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.

Julio A Lamprea-Montealegre^1,2,3, Erin Madden^2,3, Sri Lekha Tummalapalli^2,3,4, Chi D Chu^1,2, Carmen A Peralta^1,2,5, Yuxian Du⁶, Rakesh Singh⁶, Sheldon X Kong⁶, Delphine S Tuot^1,2, Michael G Shlipak^1,2,3, Michelle M Estrella^1,2,3

¹Department of Medicine, University of California, San Francisco, San Francisco, CA.

²Kidney Health Research Collaborative, University of California, San Francisco, San Francisco, CA.

³San Francisco Veterans Administration Health Care System, San Francisco, CA.

⁴Division of Healthcare Delivery Science & Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.

⁵Cricket Health, Inc., San Francisco, CA.

⁶Bayer Healthcare U.S. LLC, Whippany, NJ.

PubMed PMC DOI PDF

Abstract

OBJECTIVE: To assess the prevalence and correlates of prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1-RA) in individuals with type 2 diabetes mellitus (T2DM) with and without chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: This was a cross-sectional analyses of SGLT2i and GLP1-RA prescriptions from 1 January 2019…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.